Abstract
Allergen immunotherapy is the only disease-modifying treatment for allergic diseases with proven sustained efficacy, but long treatment duration, chronic exposure to aluminum salts as well as allergic side-effects are major drawbacks. We hereby evaluate an innovative plant-based vaccine platform of in vivo assembled micro-sized bioparticles (BPs) expressing recombinant allergens for improved safety and immunogenicity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
